

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	09/647,586	12/22/2000	Eric Argirios Kitas	RDID0063US	8561
	32012	7590 07/02/2003			
	THE LAW OFFICE OF JILL L. WOODBURN, L.L.C.			EXAMINER	
JILL L. WOODBURN 128 SHORE DR.			EPPS, JANET L		
	OGDEN DUNES, IN 46368			ART UNIT	PAPER NUMBER
				1635 DATE MAILED: 07/02/2003	13

Please find below and/or attached an Office communication concerning this application or proceeding.

## Notice to Comply Application No. O9/647,586 Examiner Janet Epps Applicant(s) Kitas et al. Art Unit 1635

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):				
a C	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 DG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).			
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).			
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).			
C	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."			
a	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).			
☐ 6 "	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the Sequence Listing" as required by 37 C.F.R. 1.821(e).			
App	7. Other   Dicant Must Provide:  An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".			
	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry the specification.			
appli	A statement that the content of the paper and computer readable copies are the same and, where icable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 5(d).			
For	questions regarding compliance to these requirements, please contact:			
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entIn Software Program Support			

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Technical Assistance......703-287-0200

Application/Control Number: 09/647,586

Art Unit: 1635

## Sequence Information

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. The amino acid sequences set forth in the specification as filed, for example, page 6, includes L amino acids, not just D amino acids. See the attached CRF Problem Report.

A complete response to this Office Action requires that Applicants comply with the sequence rules, and that pending rejections be addressed. Any response that does not address all of these issues will be held as non-responsive. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Application/Control Number: 09/647,586

Art Unit: 1635

Page 3

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L. Epps-Ford, Ph.D. whose telephone number is 703-308-8883. The examiner can normally be reached on M-T, Thurs-Fri, 8:30AM-6: 30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John L. LeGuyader can be reached on 703-308-0447. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-746-5143 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

anet L. Epps-Ford Ph.D.

Examiner
Art Unit 1635

*JLE* June 30, 2003